CNP-201 in Subjects With Peanut Allergy

Summary

This study is a Phase 1b/2a clinical trial to assess the safety, tolerability, and pharmacodynamics of multiple ascending doses (Escalation Phase) of CNP-201 with the goal of identifying a safe and tolerable dose level to be evaluated further in a larger number of subjects (Expansion Phase).

Timeline

Start

2022-03-14

Primary completion

2023-12-12

Completion

2023-12-12

Outcome

Outcome not reported

Stopped (Enrollment): “Lagging Enrollment and Administrative Reasons”

Drugs

Indications